The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier position is being challenged by the IL-17 inhibitors secukinumab (Novartis’s Cosentyx), ixekizumab (Eli Lilly’s Taltz), and brodalumab (Bausch Health’s Siliq, Leo Pharma’s Kyntheum, Kyowa Hakko Kirin’s Lumicef) and by the IL-12/23 inhibitor ustekinumab (Janssen’s Stelara). With the approvals of the IL-23 inhibitors guselkumab (Janssen’s Tremfya), tildrakizumab (Merck & Co. / Almirall / Sun Pharma’s Ilumya / Ilumetri), and, more recently, risankizumab (AbbVie / Boehringer Ingelheim’s Skyrizi), another effective drug class has been introduced to this competitive market. The landscape for the established biologics will change even further with the increasing availability and use of biosimilars.
Geographies: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 24 country-specific interviews with thought leaders. Supported by survey data collected for this and other DRG research.
Epidemiology: Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.
Emerging therapies: Phase III/PR: 7 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.
Forecast: 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2029, segmented by brands/generics and epidemiological subpopulations.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.